What tesamorelin is
Tesamorelin is a synthetic 44-amino acid peptide analogue of growth hormone-releasing hormone (GHRH). The FDA approved it in November 2010 under the brand name Egrifta (NDA 022505) for reduction of excess abdominal fat in HIV-infected adults with antiretroviral therapy-related lipodystrophy. A reformulated version, Egrifta SV, was approved in 2019. Both are developed by Theratechnologies and marketed in the US by EMD Serono.
The peptide sequence matches human GHRH(1-44) but carries a trans-3-hexenoic acid group conjugated to the N-terminal tyrosine residue. This hexenoyl modification improves enzymatic stability relative to native GHRH, which is cleaved rapidly by dipeptidyl peptidase IV and circulates with a half-life of approximately 12 minutes. Tesamorelin prolongs active concentration without requiring albumin conjugation or PEGylation, the strategies used by longer-acting GH-axis peptides.
Its approved indication is narrow: excess visceral adiposity in HIV-infected adults on antiretroviral therapy. Use outside that indication is off-label and lacks Phase 3 support as of mid-2026.
Mechanism of action: pituitary stimulation and IGF-1
Tesamorelin binds GHRH receptors on anterior pituitary somatotroph cells, triggering intracellular cAMP signaling and driving both GH synthesis and pulsatile GH release. The compound preserves the pulsatile pattern of GH secretion that endogenous GHRH normally produces, which distinguishes it from exogenous recombinant GH administration.
GH released through this pathway acts on hepatocytes and peripheral tissues to stimulate IGF-1 production. In the Phase 3 trials, treated patients showed approximately 53% increases in serum IGF-1 at 24 weeks compared to baseline. The FDA label flags this: the long-term consequences of sustained IGF-1 elevation have not been fully characterized, and the drug carries a contraindication for patients with active or suspected malignancy.
Researchers comparing GHRH analogues in study design should note that tesamorelin, CJC-1295 without DAC (modified GRF 1-29), and sermorelin all target the same GHRH receptor but differ substantially in half-life, molecular weight, and structural modification strategy. The CJC-1295 and Ipamorelin research guide covers the secretagogue pathway in parallel detail and is a useful reference for protocol design involving GHRH analogues.
Tesamorelin research: key trial results
The pivotal Phase 2 randomized trial was published by Falutz and colleagues in the New England Journal of Medicine in December 2007 (Falutz et al., NEJM 2007, n=412). Patients were randomized 2:1 to tesamorelin 2 mg subcutaneously daily or placebo and followed for 12 months. Visceral adipose tissue (VAT), measured by CT scan at the L4-L5 vertebral level, decreased by 10.9% (21 cm²) in treated subjects versus a small increase in placebo recipients.
Two Phase 3 double-blind, placebo-controlled trials followed. A pooled analysis published in the Journal of Clinical Endocrinology and Metabolism (Falutz et al., JCEM 2010, n=816) found a net VAT reduction of 15.4% at week 26. Patients who continued tesamorelin through week 52 reached approximately 18% VAT reduction. Adverse event rates were similar between treatment and placebo arms, and no hepatic safety signals were identified.
Both Phase 3 trials used CT-measured VAT at the L4-L5 level as the primary efficacy endpoint. Waist circumference was a secondary measure and decreased significantly in treated patients. Triglycerides improved, and the treated group showed no statistically significant differences in HbA1c or fasting glucose relative to placebo at week 26.
A separate Phase 3 trial with a safety extension published in the Journal of Acquired Immune Deficiency Syndromes (Falutz et al., JAIDS 2010, n=404) documented the same 18% VAT reduction at 26 weeks, again without significant alteration of fasting glucose or HbA1c in the overall population.
Metabolic outcomes and the evidence scope
Stanley and colleagues examined metabolic parameters within the Phase 3 population (Stanley et al., 2012, PMID 22495074). Patients who achieved the greatest VAT reductions showed the largest improvements in triglyceride levels and total-to-HDL cholesterol ratios, indicating that the metabolic benefit tracks with the magnitude of fat loss rather than being an independent drug effect on lipid metabolism.
A subsequent randomized trial assessed hepatic steatosis (PMID 25038357). Six months of tesamorelin was associated with reduced liver fat fraction measured by MR spectroscopy, a finding that attracted interest in non-alcoholic fatty liver disease research independent of the HIV context. Phase 2 trials in NASH populations were subsequently registered on ClinicalTrials.gov, though no Phase 3 data exists for non-HIV liver indications as of 2026.
On glycemia: across the Phase 3 program, fasting glucose and insulin did not significantly differ from placebo at the group level at 26 weeks. Patients with pre-existing diabetes or impaired glucose tolerance were excluded from the registration trials, so the glycemic safety data does not generalize to higher-risk populations. The prescribing information includes a precaution for glucose monitoring in at-risk patients.
Evidence limitations and off-label research status
Every registration trial enrolled HIV-positive adults on antiretroviral therapy with documented excess visceral adiposity. The compound has not been studied in Phase 3 trials in healthy adults, general obesity populations, or athletes. The selection criteria used in the FDA program make it difficult to extrapolate efficacy or safety data to non-HIV research contexts.
The VAT reduction does not persist after stopping the drug. Patients who switched from tesamorelin to placebo at week 26 in the Phase 3 trials returned to near-baseline VAT values by week 52. This reversal makes tesamorelin an ongoing maintenance treatment in the clinical setting, not a finite intervention with durable effects.
Research on cognitive effects in aging HIV-positive adults has been pursued in Phase 2 (NCT02572323, completed 2023). Results showed a trend toward improved neurocognitive performance in the tesamorelin arm, but the between-group difference did not reach statistical significance, and no Phase 3 cognition trials have been registered.
A 2025 meta-analysis of randomized controlled trials (PMID 41545261) synthesized body composition, hepatic fat, metabolic, and safety outcomes across the tesamorelin RCT literature. The pooled estimates confirmed the VAT reduction signal and the transient IGF-1 elevation, and found no significant change in lean body mass across studies. This analysis is the most comprehensive synthesis of the clinical trial record as of 2026.
The sustained IGF-1 elevation is a practical constraint for any research protocol involving subjects at elevated cancer risk. The FDA label excludes patients with active malignancy from clinical use, and this caution applies when designing study eligibility criteria for research protocols.
Handling and storage for research protocols
Tesamorelin is supplied as a lyophilized powder. The clinical formulation uses sterile water for injection as diluent rather than bacteriostatic water, since the reconstituted product is formulated for single-use administration. Research protocols using tesamorelin should apply standard lyophilized peptide storage practices: keep unreconstituted powder at 2-8 degrees C away from light and humidity, and use within the stated shelf life on the vial label.
Tesamorelin's molecular weight is approximately 5135 Da. The peptide dosing calculator accommodates this molecular weight for concentration and volume calculations when preparing research solutions. Reconstituted solutions should be used promptly given the lack of bacteriostatic preservative in the standard formulation.
The subcutaneous injection route used in all registration trials (abdominal region, 2 mg daily) aligns with standard protocol practice for peptides in this class. Tesamorelin does not require the meal-timing considerations associated with ghrelin receptor agonists, since it acts upstream on the GHRH axis. Researchers designing protocols combining tesamorelin with other secretagogues should consult the CJC-1295 and Ipamorelin guide for detail on pathway overlap and potential additive GH stimulation.